Source link : https://www.newshealth.biz/health-news/tafasitamab-regimen-improves-pfs-in-relapsed-refractory-follicular-lymphoma/
At the recent American Society of Hematology (ASH) annual meeting, late-breaking phase III data demonstrated that adding tafasitamab (Monjuvi) to lenalidomide (Revlimid) and rituximab (Rituxan) significantly improved progression-free survival (PFS) in relapsed/refractory follicular lymphoma with no excessive toxicity. In this final of four exclusive episodes, MedPage Today brought together three expert leaders in the field, […]
Author : News Health
Publish date : 2025-01-09 18:01:40
Copyright for syndicated content belongs to the linked Source.
Categories